Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Endomorphin-1 & Endomorphin-2 peptide icon, one bubble per amino acidEndomorphin-1 & Endomorphin-24 residuesYPWFEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Endomorphin-1 & Endomorphin-2

~2-8 minutes half-life·Injection

Also known as: EM-1, EM-2, Endomorphin 1

Four amino acids. That's all it takes to build the most selective mu-opioid receptor agonist the human body produces. Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) and Endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) bind MOR with 4,000 to 15,000 fold selectivity over delta and kappa receptors. Discovered by Zadina and colleagues in 1997 [1], these tetrapeptides still have no approved clinical application. The native forms degrade in plasma within minutes. One cyclized analog, CYT-1010, reached Phase I and showed analgesia without respiratory depression. Researchers studying opioid pharmacology and next-generation pain drug design track these peptides closely.

What Is Endomorphin-1 & Endomorphin-2?

Endomorphin-1 (EM-1; Tyr-Pro-Trp-Phe-NH2) and Endomorphin-2 (EM-2; Tyr-Pro-Phe-Phe-NH2) are endogenous tetrapeptides and the most selective mu-opioid receptor agonists ever identified. Zadina's group isolated them from bovine and human brain tissue in 1997 [1]. Before that discovery, no one had found the endogenous ligand for the mu receptor, the same receptor morphine targets.

EM-1 binds MOR at a Ki of roughly 360 pM. That's 4,000 fold selective over delta and 15,000 fold over kappa. EM-2 binds at about 690 pM, with even higher mu/delta selectivity at 13,400 fold. They differ by a single amino acid at position three (tryptophan vs. phenylalanine), yet that swap changes everything about their downstream signaling and distribution in the brain.

In practice, these peptides are research tools. EM-1 concentrates in the nucleus accumbens, cortex, and dorsal root ganglia; EM-2 clusters in the spinal cord and lower brainstem. Both produce potent analgesia in rodent pain models when administered directly into the brain or spinal cord. Peripheral injection is mostly pointless; plasma dipeptidyl peptidase IV (DPP-IV) shreds the Tyr-Pro bond within 2 to 8 minutes.

The real excitement is in the analogs. CYT-1010, a cyclized EM-1 derivative, completed Phase I. A 2020 review reports analgesia and no respiratory depression at the doses tested (Webster and Schmidt)[2]. That is the holy grail of opioid drug design. PubMed lists 913 papers on endomorphins. They aren't sold as consumer peptides, and no self-dosing community exists. This is pure pharmacology research, and the data is genuinely promising for future pain therapeutics.

How Endomorphin-1 & Endomorphin-2 Works

EM-1 and EM-2 both activate the mu-opioid receptor (MOR/OPRM1), but they do it differently. That difference matters.

Both peptides trigger Gi/Go protein-coupled signaling. Adenylyl cyclase goes quiet. cAMP drops. Voltage-gated N-type and P/Q-type calcium channels close, reducing presynaptic neurotransmitter release. G protein-coupled inwardly rectifying potassium channels (GIRKs) open, hyperpolarizing the neuron. The net result is suppressed nociceptive signaling.

EM-2 is a biased agonist. It preferentially recruits beta-arrestin over G protein signaling compared to reference agonists like DAMGO. Lower operational efficacy for G protein-mediated responses in mature neurons may explain the reduced respiratory depression and tolerance profiles spotted in preclinical models [3].

At the systems level, the two peptides split territory. EM-1 handles supraspinal analgesia through MOR in the periaqueductal gray, rostral ventromedial medulla, and thalamus. EM-2 engages descending pathways that release dynorphin A (kappa receptors) and met-enkephalin (delta-2 receptors), creating a multi-receptor analgesic cascade. EM-2 immunoreactive fibers sit right next to serotonergic neurons in the RVM, linking endomorphin signaling to descending serotonergic pain modulation.

Outside pain, EM-2 produces hypotension and bradycardia through MOR activation in the nucleus tractus solitarius [4]. Both peptides suppress pro-inflammatory cytokine release via MOR on macrophages and lymphocytes, inhibiting p38 MAPK signaling [5].

Endomorphin-1 & Endomorphin-2 Benefits

  • Endomorphin benefits center on opioid receptor pharmacology and next-generation analgesic drug design, not consumer self-administration.
  • Highest known mu-opioid selectivity of any endogenous peptide. EM-1 hits 4,000 fold mu/delta and 15,000 fold mu/kappa (Zadina et al.)[1]. No other endogenous ligand comes close.
  • Potent supraspinal and spinal antinociception in rodent pain models. EM-1 is approximately 3 fold more potent than EM-2 for supraspinal analgesia in hot-plate and tail-flick assays [6].
  • Reduced respiratory depression vs. morphine at equianalgesic doses in preclinical studies. The CYT-1010 Phase I trial confirmed this held in humans for at least one stabilized analog [2].
  • Anti-inflammatory activity in both acute and chronic peripheral inflammation models through MOR signaling on immune cells [5]. A benefit most people don't associate with opioid peptides.
  • Slower tolerance buildup compared to morphine in repeated-dosing animal protocols. Not "no tolerance," but a wider window before analgesic doses need escalation [3].
  • EM-2's biased agonism profile (beta-arrestin-preferring) makes it a template for designing opioids that separate analgesia from respiratory depression.

Endomorphin-1 & Endomorphin-2: Science vs Community Consensus

Science Only
Scientific Evidence
Moderate
Based on 11 key studies·Research only

Endomorphin-1 and Endomorphin-2 are the most selective endogenous mu-opioid receptor agonists identified.

Dosing studied: No valid human dose range for native peptides. Preclinical rodent: ICV 1–30 nmol, IT 0.1–30 nmol.
Read the evidence (key study, limitations)

Potent antinociception in preclinical models is well-established. No validated human dosing for native peptides exists, so this page lists no dose. CYT-1010 (cyclized EM-1 analog) showed analgesia without respiratory depression in Phase I.

Key Study

Zadina et al. 1997 (PMID 9087409): discovery of EM-1/EM-2 as MOR endogenous agonists; CYT-1010 Phase I (Webster and Schmidt 2020, PMID 31165885): first human data for an EM-1 analog showing analgesia without respiratory depression

Limitations

No human PK/PD data for native endomorphins. Rapid plasma DPP-IV degradation (t½ ~2–8 min) renders peripheral dosing essentially futile without analog modification. No precursor gene identified: biosynthetic origin remains unresolved. Preclinical to human translation is uncertain for all opioid peptides.

Community Experience
Weak
3.5/5
Based on <5 Reddit mentions total

No consumer or self-administration use documented.

Community dosing: N/A: no community protocols exist
Read the reports (common issues 3)

Endomorphin is not sold as a research-grade consumer peptide and has no self-dosing reports on Reddit, forums, or any grey-market channel. Essentially absent from community discourse.

What users report (0)
    Common issues (3)
    • Not commercially available: lab synthesis supply only
    • No consumer-accessible source exists
    • Opioid class risks discourage self-administration even in research-aware communities
    Science-Only Evidence

    All data is from published preclinical research and one Phase I study of an analog (CYT-1010). Zero consumer/community use. Community verdict fields reflect absence of data, not negative experience.

    Endomorphin-1 & Endomorphin-2 Dosage Guide

    No established human dose

    No human dose has been established for endomorphin-1 or endomorphin-2, so this page shows no dose tiers. PubMed lists no study that gave either native peptide to people. The closest human data come from CYT-1010, a cyclized endomorphin-1 analog. A 2020 review reports that its phase 1 study found analgesia and no respiratory depression at the doses tested [2]. That analog is a different molecule, and the review's abstract gives no dose.

    Note:

    This is a research reagent, not a consumer peptide. No standard vial exists in the research-peptide market.

    Endomorphin is sold only as a lab reagent for research; typical custom synthesis delivers 1 mg lyophilized. Reconstitution math only: 2 mL bacteriostatic water gives 500 mcg/mL, so each unit on a U-100 insulin syringe holds 5 mcg.

    No published study has given native endomorphin to people, so no dose is listed here. No published human pharmacokinetic data supports any peripheral SC dose either. The Tyr-Pro bond gets cleaved by DPP-IV in minutes, and barely anything crosses the blood-brain barrier from a peripheral route.

    Swirl gently after reconstitution. Don't vortex. C-terminal amidation is what keeps these peptides binding MOR; rough handling won't help stability. Store lyophilized at -20C desiccated. Reconstituted, you get maybe 7 days at 2-8C. Prepare small aliquots and minimize freeze-thaw cycles.

    A valid CoA confirms sequence (EM-1: Tyr-Pro-Trp-Phe-NH2 or EM-2: Tyr-Pro-Phe-Phe-NH2) with HPLC purity at least 95% and mass spec verification.

    Cycling

    No established human cycling protocol exists. The extremely short half-life of native endomorphins (minutes) makes sustained dosing impractical without stabilized analog formulations or continuous infusion. In preclinical repeated-dosing studies, tolerance develops within days. Any investigational protocol must include naloxone availability and medical supervision. Cycling parameters shown are theoretical placeholders based on opioid peptide class considerations.

    Endomorphin-1 & Endomorphin-2 reconstitution math
    Vial and water math with syringe visualization. No preset dose.

    Or use the universal Peptide Calculator for any peptide.

    How to Use Endomorphin-1 & Endomorphin-2

    1. 1
      Step 1

      Lyophilized endomorphin is sold only as a lab reagent for research. Confirm sequence and purity on the Certificate of Analysis before proceeding.

    2. 2
      Step 2

      Reconstitute by adding 2 mL bacteriostatic water to a 1 mg vial. Swirl gently until dissolved. This gives 500 mcg/mL, or 5 mcg per unit on a U-100 insulin syringe.

    3. 3
      Step 3

      A 2 mg vial with the same 2 mL gives 1,000 mcg/mL, or 10 mcg per unit. Check which vial you hold before every draw.

    4. 4
      Step 4

      No human study tested subcutaneous use, so this guide gives no injection steps, dose or unit count.

    5. 5
      Step 5

      Have naloxone 0.4 mg IV/SC pre-positioned before any administration. Monitor respiratory rate and SpO2 continuously. Monitor blood pressure and heart rate at 5, 15, and 30 minutes afterward.

    6. 6
      Store reconstituted vial at 2-8C

      Use within 7 days.

    FOR RESEARCH USE ONLY. No human dosing protocol exists for native endomorphin.

    Alternative Routes

    Subcutaneous (SC)

    Orders of magnitude higher dose required vs. ICV to achieve any CNS analgesic effect; exact ratio not established in humans

    DPP-IV in plasma degrades the Tyr-Pro bond within 2–8 minutes. BBB penetration is very low. SC administration is the most practical peripheral route but produces minimal central analgesia with native peptide. Stabilized analogs (D-amino acid, lipid-conjugated) are specifically designed to make SC viable.

    Intravenous (IV)

    Faster plasma exposure but same rapid DPP-IV degradation; any peripheral analgesic effect is transient (<5 min)

    IV route is used in research settings for pharmacokinetic studies and cardiovascular effect measurements. Useful for studying peripheral opioid receptor effects on immune cells and gut. Does not bypass BBB.

    Intrathecal (IT)

    Preclinical rodent: 0.1–30 nmol IT vs. 1–30 nmol ICV; spinal route engages EM-2 descending pathways more strongly

    Requires sterile catheter placement and medical/surgical infrastructure. CSF degradation is slower than plasma (>2 hours for complete inactivation). Produces primarily spinal antinociception. EM-2 particularly active at spinal level. Only viable in medical research settings.

    Intracerebroventricular (ICV)

    Rodent reference doses: 1–30 nmol ICV produce dose-dependent antinociception; EM-1 ~3× more potent than EM-2 supraspinally

    Requires neurosurgical implantation of a cannula. Completely impractical outside laboratory animal research. Produces the clearest pharmacological data and is the source of most published endomorphin analgesic characterization. Not applicable to human self-administration.

    Mixing your own vial? Use the Endomorphin-1 & Endomorphin-2 reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

    Endomorphin-1 & Endomorphin-2 Stacking Protocols

    Works With

    Avoid

    Benzodiazepines (diazepam, alprazolam, clonazepam, etc.)

    Additive CNS and respiratory depression. Combined opioid + benzodiazepine is the leading cause of opioid overdose death. Potentially fatal.

    Do not combine
    Opioid analgesics (morphine, fentanyl, oxycodone, hydromorphone)

    Additive respiratory depression and overdose risk. Mu-opioid receptor saturation: no additional analgesic benefit, compounded toxicity.

    Do not combine
    Gabapentinoids (gabapentin, pregabalin)

    Additive respiratory depression risk when combined with opioids: FDA black box warning class.

    Do not combine
    MAO inhibitors (phenelzine, tranylcypromine, selegiline)

    Risk of unpredictable potentiation of opioid effects; can cause serotonin syndrome or severe respiratory/cardiovascular events.

    Do not combine
    Alcohol

    Potentiates sedation and respiratory depression; significantly lowers overdose threshold.

    Do not combine

    Estimated Cost

    Endomorphin-1 & Endomorphin-2 Side Effects

    Respiratory depression is the leading cause of opioid overdose death, and endomorphins are mu-opioid agonists. Start there.

    Preclinical data does show reduced respiratory depression compared to morphine and DAMGO at equianalgesic doses. CYT-1010 (an EM-1 analog) reached Phase I with no observed respiratory depression. That is encouraging. It is not the same as safe. "Reduced" still means present, dose-dependent, and life-threatening if monitoring fails. Naloxone must be immediately accessible in any research setting; this is non-negotiable.

    Human data on native endomorphins is essentially absent. Total human exposure through published research is extremely small, concentrated in the CYT-1010 Phase I trial of the cyclized analog. Side effect frequency numbers from preclinical rodent work cannot be translated to human incidence rates with confidence.

    In animal models, observed effects include sedation, reduced locomotor activity, and motor impairment at higher doses. Gastrointestinal motility drops, producing constipation, though stabilized analogs show less GI impact than morphine. EM-2 produces hypotension through nucleus tractus solitarius activation and bradycardia through central autonomic pathways [4]. Blood pressure and heart rate monitoring is mandatory during any research administration.

    Tolerance to the analgesic effect develops with repeated dosing. Onset appears slower than morphine tolerance in head-to-head preclinical comparisons, but it still develops within 3 to 7 days. Physical dependence follows chronic exposure. Naloxone-precipitated withdrawal symptoms occur in dependent animals.

    EM-2 shows faster acute desensitization than EM-1 due to preferential beta-arrestin-2 recruitment and rapid MOR internalization. Re-dosing before receptor re-sensitization produces diminishing returns quickly.

    Urinary retention and miosis are expected opioid class effects. The extremely short plasma half-life (2 to 8 minutes for native forms) limits the duration of adverse effects after a single dose, which is a double-edged feature; it also limits any therapeutic benefit.

    When to stop and seek emergency care: respiratory rate below 10 breaths per minute, SpO2 below 92%, heart rate below 50 bpm, systolic blood pressure below 90 mmHg, excessive sedation, or loss of consciousness. Administer naloxone 0.4 mg IV or SC immediately.

    Pregnancy and breastfeeding: opioid peptides may cross the placental barrier. No safety data exists for any population, including pediatric.

    Common Issues & Solutions

    No analgesic effect via SC/IV route: this is expected. Native endomorphins are degraded by plasma DPP-IV within minutes and do not meaningfully cross the blood-brain barrier at peripheral doses. Only central routes (ICV/IT) produce reliable antinociception in preclinical models.

    Duration of action is only ~15–30 minutes even via direct CNS administration. This is intrinsic to the molecule: rapid receptor desensitization and short half-life limit duration. Stabilized analogs (D-amino acid variants, lipid conjugation, CYT-1010) were designed to solve this.

    Native endomorphin is not sold as a consumer peptide. It is sold only as a lab reagent for research, by custom or catalog synthesis: not in reconstituted vials. Custom synthesis lead times run 2–8 weeks.

    Tolerance develops within 3–7 days of repeated dosing in preclinical models: faster initial course than morphine tolerance due to rapid MOR desensitization. Acute tolerance (desensitization) can appear within the same dosing session if re-dosed before receptor re-sensitization.

    Respiratory depression remains a class risk even at apparently "reduced" doses. Preclinical improvement over morphine does not guarantee a safe therapeutic window in humans. Naloxone reversal must be immediately available in any research setting: non-negotiable.

    Ask AI about this page

    Ask AI for a second opinion on Endomorphin-1 & Endomorphin-2 dosing and side effects

    Contraindications

    • Pregnancy and breastfeeding: opioid peptides may cross the placental barrier
    • History of substance use disorder or opioid addiction
    • Respiratory insufficiency or compromised airway including sleep apnea
    • Severe hepatic impairment affecting peptidase metabolism
    • Concurrent use of MAO inhibitors
    • Known hypersensitivity to endomorphin peptides
    • Paralytic ileus or gastrointestinal obstruction
    • Unmonitored settings without access to naloxone reversal
    • Pediatric populations (no safety data)
    • Traumatic brain injury with elevated intracranial pressure
    • Severe cardiovascular instability (endomorphins produce hypotension and bradycardia)

    Drug Interactions

    • Benzodiazepines: additive CNS and respiratory depression; potentially fatal combination
    • Other opioid agonists (morphine, fentanyl, oxycodone): additive respiratory depression and overdose risk
    • Alcohol: potentiates sedation and respiratory depression
    • CNS depressants including barbiturates, sedative antihistamines, and general anesthetics
    • MAO inhibitors: risk of unpredictable potentiation of opioid effects
    • DPP-IV inhibitors (sitagliptin, vildagliptin): may reduce endomorphin degradation and prolong activity
    • Naloxone and naltrexone: opioid receptor antagonists that fully reverse endomorphin effects
    • Gabapentinoids (gabapentin, pregabalin): increased risk of respiratory depression when combined with opioids
    • Antihypertensive agents: additive hypotensive effects particularly with EM-2
    • Beta-blockers: additive bradycardia risk due to central cardiovascular effects of endomorphins

    Product Quality

    Recommended Monitoring

    TestWhenTarget
    Respiratory rateContinuous during any research administration session>12 breaths/min; alert at <10; treat at <8
    Pulse oximetry (SpO2)Continuous during and 30 minutes post-administration>95%; treat SpO2 <92% with naloxone and supplemental O2
    Blood pressurePre-dose, 5 min, 15 min, 30 min post-doseSystolic >90 mmHg; treat significant hypotension with position change and IV fluids
    Heart rateContinuous during administration>50 bpm; treat symptomatic bradycardia with atropine
    Naloxone availability (not a lab test)Before any administration: must be pre-positionedNaloxone 0.4 mg SC/IV immediately accessible; repeat dosing may be needed
    Respiratory rate

    Respiratory depression is the primary acute opioid fatality risk; must be detected immediately

    Pulse oximetry (SpO2)

    Hypoxia is the downstream consequence of respiratory depression; provides objective early warning

    Blood pressure

    EM-2 produces central hypotension via NTS activation: risk of syncope in research subjects

    Heart rate

    Bradycardia risk with EM-2 via central autonomic pathways

    Naloxone availability (not a lab test)

    Opioid reversal is mandatory safety requirement; delay is life-threatening

    Endomorphin-1 & Endomorphin-2 Before and After

    Minutes 0-2

    Rapid onset of antinociception following central (ICV or IT) administration in preclinical models. Peak analgesic effect reached within 1-2 minutes. Measurable mu-opioid receptor activation with dose-dependent responses in tail-flick and hot-plate assays.

    Minutes 2-15

    Sustained peak analgesia. EM-1 produces stronger supraspinal antinociception; EM-2 engages additional spinal descending pathways. Cardiovascular effects (hypotension, bradycardia) measurable with EM-2. Rapid plasma degradation by DPP-IV begins immediately.

    Minutes 15-30

    Gradual decline in analgesic effect as receptor desensitization and peptide degradation proceed. Acute tolerance (desensitization to the same agonist) begins to develop. Antinociceptive effect disappears completely within approximately 30 minutes after a single dose.

    30 minutes - 2 hours

    Return to baseline nociceptive thresholds. Complete plasma clearance of native peptides. CSF degradation proceeds more slowly (>2 hours for complete inactivation). Acute antinociceptive tolerance is measurable if re-dosed within this window.

    Days 3-7
    repeated dosing

    Progressive tolerance development with repeated administration, though slower onset than morphine in preclinical comparisons. Physical dependence may emerge with chronic central infusion protocols. Naloxone-precipitated withdrawal observable in dependent animals.

    What to Expect

    Minutes 0 to 2 (Rapid onset, central administration): Peak analgesia hits within 1 to 2 minutes after intracerebroventricular dosing in rodent models. This is exclusively preclinical data. MOR activation is immediate and dose-dependent in hot-plate and tail-flick assays. Sedation, respiratory rate decrease, and motor impairment appear at higher doses. EM-2 produces measurable hypotension and bradycardia at this stage. No human self-administration data exists for native endomorphin.

    Minutes 2 to 15 (Sustained peak): Antinociception holds at its peak. EM-1 dominates supraspinally; EM-2 recruits descending pathways involving dynorphin A and met-enkephalin for broader spinal analgesia. Cardiovascular effects from EM-2 remain measurable. Sedation continues. GI motility slows. No community data.

    Minutes 15 to 30 (Declining effect): DPP-IV degradation and beta-arrestin-2 mediated MOR internalization pull the analgesic effect down. By 30 minutes after a single ICV dose, antinociception is gone. Residual sedation fades. Nociceptive thresholds return to baseline. Acute tolerance is already measurable if you re-dose within this window.

    30 minutes to 2 hours (Back to baseline): Native peptide is fully cleared from plasma. Cerebrospinal fluid degradation is slower, taking over 2 hours for complete inactivation. Re-dosing during this period produces a blunted response due to MOR desensitization.

    Days 3 to 7 (Repeated dosing, tolerance window): Progressive analgesic tolerance builds with daily dosing. Onset is slower than morphine but still within the same order of magnitude. Physical dependence emerges with chronic central infusion. Dose escalation becomes necessary. Abrupt discontinuation or naloxone challenge produces observable withdrawal signs in dependent animals.

    Detailed Timeline: Science vs Community

    Minutes 0–2
    Science

    Peak analgesic effect within 1–2 minutes after ICV administration in rodent models. Dose-dependent antinociception in hot-plate and tail-flick assays. MOR activation measurable immediately.

    Community

    No human self-administration data exists.

    Minutes 2–15
    Science

    Maintained peak antinociception. EM-1 stronger supraspinally; EM-2 engages additional descending pathways via dynorphin A and met-enkephalin. Cardiovascular effects (hypotension, bradycardia) measurable with EM-2.

    Community

    No data.

    Minutes 15–30
    Science

    Gradual analgesic decline as DPP-IV degradation proceeds and MOR desensitization (beta-arrestin-2 internalization) accumulates. Antinociception disappears within ~30 minutes after a single ICV dose.

    Community

    No data.

    30 min – 2 hours
    Science

    Complete plasma clearance of native peptides. CSF inactivation slower (>2 hours for complete degradation). Acute antinociceptive tolerance measurable if re-dosed within this window.

    Community

    No data.

    Days 3–7 (repeated dosing)
    Science

    Progressive analgesic tolerance with repeated administration: slower onset than morphine but within the same order of magnitude. Physical dependence emerges with chronic central infusion. Naloxone-precipitated withdrawal signs observable in dependent animals.

    Community

    No data.

    Pharmacokinetics

    Half-Life
    5min
    Bioavailability
    ICV/IT: direct CNS delivery; IV/SC: very low due to rapid plasma degradation by DPP-IV
    Tmax
    <2 minutes ICV; effects disappear within 30 minutes
    Data Confidence
    low

    Source: Plasma t1/2 estimated at 2-8 minutes; rapid degradation by DPP-IV and aminopeptidases. CSF degradation >2 hours (Fichna et al., 2007, PMID 17329549; Horvath, 2000, PMID 11337033)

    Pharmacokinetics: Active Dose Over Time

    t½ = ~2-8 minutes (plasma); rapid enzymatic degradation in vivo

    Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

    Molecular Profile

    Amino Acids
    4
    Sequence
    YPWF
    HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
    Identifiers
    CAS: EM-1: 189388-22-5; EM-2: 141801-26-5PubChem 5311080 (opens in a new tab)

    Who Should Consider Endomorphin-1 & Endomorphin-2

    • Opioid receptor pharmacology and signaling researchers
    • Pain neuroscience investigators studying endogenous analgesia pathways
    • Medicinal chemists developing stabilized opioid peptide analogs
    • Neuroscience researchers studying biased agonism at mu-opioid receptors
    • Immunology researchers investigating opioid-immune interactions
    • Cardiovascular researchers studying central autonomic regulation

    Related Peptides

    What Changed for Endomorphin-1 & Endomorphin-2

    No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

    Peptide Schedule Research TeamReviewed Apr 7, 202611 Citations

    References

    1. [1]A potent and selective endogenous agonist for the mu-opiate receptor (opens in a new tab)PubMed (opens in a new tab)PubMed
    2. [2]Dilemma of Addiction and Respiratory Depression in the Treatment of Pain: A Prototypical Endomorphin as a New Approach (opens in a new tab)PubMed (opens in a new tab)Review
    3. [3]Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphine (opens in a new tab)PubMed (opens in a new tab)PubMed
    4. [4]Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine (opens in a new tab)PubMed (opens in a new tab)PubMed
    5. [5]Endomorphins as agents for the treatment of chronic inflammatory disease (opens in a new tab)PubMed (opens in a new tab)PubMed
    6. [6]Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse (opens in a new tab)PubMed (opens in a new tab)PubMed

    Related Tools

    Storage & Stability

    Before Reconstitution
    Up to 24 months at -20°C, desiccated, protected from light
    After Reconstitution
    Up to 7 days at 2-8°C; prepare fresh aliquots to minimize freeze-thaw degradation
    Temperature
    -20°C lyophilized; 2-8°C (36-46°F) reconstituted

    Frequently Asked Questions

    Extremely selective. EM-1 binds MOR with a Ki of ~360 pM and has 4,000-fold selectivity over DOR and 15,000-fold over KOR. That makes endomorphins the most selective endogenous mu-opioid receptor agonists we know of; far more selective than DAMGO.

    Two problems. DPP-IV chews through the Tyr-Pro bond within minutes, and the peptide barely crosses the blood-brain barrier. You'd need massive peripheral doses to get anything meaningful into the CNS. Stabilized analogs with D-amino acid swaps or lipid conjugation are being developed to work around this.

    CYT-1010 is a cyclized EM-1 derivative that showed real analgesia in a Phase I trial, and no observed respiratory depression, which is the holy grail for opioid research. But it hasn't moved to Phase II publicly, so the program may be stalled.

    They're still mu-opioid agonists, so yes, physical dependence and withdrawal can develop with chronic use. That said, preclinical data shows slower tolerance buildup and less reward-seeking behavior compared to morphine at equivalent analgesic doses. Less addictive isn't the same as non-addictive.

    Nobody knows yet. No precursor gene or pre-pro-peptide has been identified, which is genuinely unusual for an endogenous peptide. EM-1 concentrates in the nucleus accumbens, cortex, and dorsal root ganglia; EM-2 shows up mainly in the spinal cord and lower brainstem.